Investment Review №341. The Obvious and the Unbelievable

Vadim Merkulov

Vadim Merkulov

Head of Analytics department

Everus Construction Group. Power for AI

ECG shares are worth buying, with a target price of $138

US Investment Idea

About company

Everus Construction Group (ECG) is a U.S.-based contractor specializing in electrical and network infrastructure projects. The company operates at the intersection of two key segments, data center construction and power system modernization, where demand is supported by the growth of AI and rising electricity consumption. The project portfolio is shifting toward more complex and mission-critical assets, which enhances margins and business resilience, while long-term contracts with utility companies provide stable utilization and revenue visibility.

Ticker ECG
Share price as of analysis $117,27
Target share price $138,00
Growth potential 18%

 

Share price dynamics vs. indices Day Week Month Quarter Year
ECG 5,7%  2,4%  10,5%  30,4%  199,1% 
S&P 500 1,1%  (1,8%) (3,8%) (4,8%) 16,1% 
Russell 2000 2,3%  (0,4%) (4,8%) (1,8%) 21,3% 
DJ Industrial Average 1,4%  (1,6%) (5,3%) (4,6%) 10,1% 
NASDAQ Composite Index 1,4%  (1,9%) (3,0%) (6,9%) 23,4% 

 

Price dynamics ECG, $

 

Key Investment Theses

ECG is delivering sustained financial growth. The company demonstrates solid momentum, with revenue increasing 33% y/y in 4Q25 to $1.0 billion and reaching $3.75 billion for full-year 2025 (+31.5% y/y). Growth is accompanied by improving operating performance and reflects strong project execution within the E&M segment, which remains the primary business driver. Management expects further growth to $4.1–4.2 billion in 2026, confirming continued strong demand and high capacity utilization.

Data centers are a key driver of both growth and profitability. Hyperscale and AI infrastructure projects require more complex engineering, higher reliability, and accelerated execution timelines, which increases contract value and reduces pricing pressure. This is already evident in the results: the E&M segment, which includes data center-related work, grew 44% y/y in 4Q25 to $792 million, while EBITDA increased 57% with margin expansion to 8.5%. As a result, a higher share of data center revenue is driving not only top-line acceleration but also improved earnings quality.

Backlog provides strong revenue visibility and supports earnings stability. Total backlog reached approximately $3.2 billion (+16% y/y), covering a significant portion of near-term revenue. The T&D segment increased 40%, reflecting accelerated utility investment in grid modernization, while E&M grew 13%, confirming sustained activity in data center construction. This diversified order mix supports stable capacity utilization and underpins continued financial growth over a 12–24 month horizon.

We set a target price for ECG at $138 with a “Buy” recommendation. A stop-loss is advised at the $104 level.

 

Ratio Analysis 2024A 2025A 2026E 2027E 2028E 2029E 2030E
ROE 32,9% 38,3% 28,3% 26,0% 23,2% 21,4% 19,9%
ROA 12,3% 13,4% 11,3% 12,0% 11,6% 11,9% 12,1%
ROCE 20,0% 22,8% 19,3% 19,6% 20,2% 20,6% 19,3%
Sales/Assets (x) 2,43x 2,48x 2,26x 2,22x 2,12x 2,13x 2,12x
Interest Coverage (x) 2,3x 13,3x 18,5x 24,2x 27,3x 57,9x N/A
Margins, % 2024A 2025A 2026E 2027E 2028E 2029E 2030E
Gross Margin 12% 12% 12% 12% 12% 12% 12%
EBITDA Margin 8% 9% 8% 8% 9% 9% 9%
Net Margin 5% 5% 5% 5% 5% 6% 6%
Financials, $mln 2024A 2025A 2026E 2027E 2028E 2029E 2030E
Выручка 2 850 3 746 4 160 4 685 5 070 5 374 5 696
Основные расходы -2 510 -3 292 -3 677 -4 136 -4 470 -4 739 -5 023
Валовая прибыль 339 454 483 549 599 635 673
SG&A -150 -189 -212 -225 -244 -258 -274
EBITDA 230 323 330 396 439 471 504
Амортизация -25 -29 -36 -45 -53 -61 -69
EBIT 190 265 271 324 355 377 399
Процентные выплаты (доходы) -14 -20 -15 -13 -13 -7 0
EBT 193 274 279 338 373 403 435
Налоги 50 72 71 86 95 102 110
Чистая прибыль 143 202 209 252 278 301 325
Basic EPS $2,81 $3,94 $4,07 $4,93 $5,65 $6,36 $7,15
DPS $0,00 $0,00 $0,00 $0,00 $0,32 $0,36 $0,41

16, Dostyk street, integral non-residential facility No.2, Yessil district Astana, Republic of Kazakhstan (Talan Towers Offices).

+7 7172 67 77 55 Free from landline numbers in Kazakhstan; calls from international and mobile numbers are chargeable.

7555 *free from mobile operators in Kazakhstan [email protected], [email protected]

Notify about fraudulent activities or security issues regarding this resource: fbroker.kz/trustcenter

Owning securities and other financial instruments is always associated with risks: the value of securities and other financial instruments can both rise and fall. Past investment results do not guarantee future income. In accordance with the law, the company does not guarantee or promise future returns on investments, nor does it provide guarantees regarding the reliability of potential investments or the stability of potential income.

Freedom Finance Global PLC provides brokerage (agency) services in the securities market on the territory of the Astana International Financial Center (hereinafter referred to as AFSA) in the Republic of Kazakhstan. Subject to compliance with requirements, conditions, restrictions and/or directions of the Acting Law of the AFSA, the Company is authorized to conduct the following Regulated Activities under License No. AFSA-A-LA-2020-0019: Dealing in Investments as Principal, Dealing in Investments as Agent, Managing Investments, Advising on Investments, Arranging Deals in Investments.

S&P Global ratings – “B+/B”, outlook “Positive”.

Ownership of securities and other financial instruments always involves risks: the cost of securities and other financial instruments may rise or fall. Past investment results do not guarantee future returns. In accordance with the legislation, the company does not guarantee or promise the profitability of investments in the future, does not guarantee the reliability of possible investments and the stability of the amount of possible income.

The information on the website is updated as part of keeping the data up-to-date and meeting regulatory disclosure requirements. Please note that these updates are for informational purposes only and are not marketing materials!